Exploring how long-acting medications can help end AIDS in southern Africa by 2030
Could long-acting medications facilitate "ending AIDS by 2030" in southern Africa? An allocative efficiency analysis
This study is looking at how long-lasting medications can help lower the number of new HIV cases in southern Africa by finding the best ways to use resources and improve patient support, like sending reminders and offering financial incentives, to help people stick to their treatment plans.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10663840 on NIH RePORTER |
What this research studies
This research investigates the potential of long-acting medications to significantly reduce HIV incidence in southern Africa by optimizing resource allocation and intervention strategies. It utilizes mathematical modeling to assess current spending and identifies critical interventions that could enhance the effectiveness of HIV care. The study aims to tailor strategies that maximize the impact of available tools, including SMS reminders and financial incentives, to improve patient engagement and treatment adherence. By focusing on these innovative approaches, the research seeks to address the challenges in meeting the UNAIDS 2030 goals for HIV management.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living with HIV in southern Africa who are seeking effective treatment options.
Not a fit: Patients who are not living with HIV or those who are not located in southern Africa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective strategies for managing HIV, ultimately reducing the incidence of AIDS in southern Africa.
How similar studies have performed: Previous research has shown success with similar optimization approaches in public health interventions, indicating potential for impactful outcomes in this area.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Braithwaite, Ronald Scott — New York University School of Medicine
- Study coordinator: Braithwaite, Ronald Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.